Examining the Clinical and Cost-Effectiveness in Managing Chemotherapy-Induced Severe Neutropenia

Examining the Clinical and Cost-Effectiveness in Managing Chemotherapy-Induced Severe Neutropenia

On-Demand Webcast

Val R. Adams, PharmD, BCOP
Associate Professor
Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Christopher A. Fausel, PharmD, BCPS, BCOP
Adjunct Associate Professor of Medicine
Indiana University School of Medicine
Clinical Manager, Oncology Pharmacy
Indiana University Simon Cancer Center
Indianapolis, Indiana


Intended Learners

This activity is designed for health-system pharmacists including specialty pharmacists, clinical pharmacists, oncology pharmacists and other pharmacists involved in the management of patients with chemotherapy-induced severe neutropenia.

Learning Objectives

After completing this activity, participants should be able to:

  • Explain evidence-based guidelines and recommendations for the use of prophylactic therapies within the management of chemotherapy-induced severe neutropenia
  • Outline efficacy and cost data of therapies for the management of chemotherapy-induced severe neutropenia, with respect to risk and duration reduction, length of hospitalization, indirect costs, and mortality
  • Distinguish among available G-CSF agents, including data on safety, administration, and costs
  • Translate evidence-based guidelines and recommendations, clinical effectiveness data, and health economics research in chemotherapy-induced severe neutropenia to optimize patient-centered and value-based care decisions
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release Date: December 22, 2017
Expiration Date: December 22, 2018
Estimated time to complete: 1.5 hours

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.











This activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education (UAN JA0006201-0000-18-115-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Planning Committee

The planning committee comprises Val R. Adams, PharmD, BCOP, Kyle R. Copeland, Christopher A. Fausel, PharmD, BCPS, BCOP; and Kristin Ciszeski, Raquel Gaerlan, Mary Johnson, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Adams: Advisory Board—Teva

Dr. Copeland and Dr. Fausel have disclosed no relevant financial relationships with any commercial interest.

Ms. Ciszeski, Ms. Gaerlan, Ms. Johnson, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity has been supported through an independent educational grant from Teva Pharmaceuticals